Lucid DiagnosticsLUCD +4.85%26 PS Ratio is 24.77 as of Jun. 26, 2026, which is 8% below its 10-year median of 26.96. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 91.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lucid Diagnostics's share price is $1.065.
Lucid Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.04. Hence, Lucid Diagnostics's PS Ratio for today is 24.77.
The historical rank and industry rank for Lucid Diagnostics's PS Ratio or its related term are showing as below:
LUCD'
s PS Ratio Range Over the Past 10 Years
Min: 8.68 Med: 26.96 Max: 2178
Current: 25.09
During the past 7 years, Lucid Diagnostics's highest PS Ratio was 2178.00. The lowest was 8.68. And the median was 26.96.
LUCD's PS Ratio is ranked worse than 91.92% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs LUCD: 25.09
During the past 7 years, Lucid Diagnostics's highest 3-Year average Revenue per Share Growth Rate was 66.30% per year. The lowest was 47.10% per year. And the median was 56.70% per year.
Back to Basics: PS Ratio
Lucid Diagnostics (NAS:LUCD) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lucid Diagnostics PS Ratio Related Terms
Lucid Diagnostics PS Ratio Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lucid Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lucid Diagnostics's Share Price of today is $1.065. Lucid Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lucid Diagnostics (LUCD) has a PS Ratio of 24.77 as of Jun. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lucid Diagnostics and its competitors. This is near median its historical median of 26.96. Over the past decade, Lucid Diagnostics' PS Ratio has ranged from 8.68 to 2,178.00. According to the industry distribution chart, Lucid Diagnostics ranks #739 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 91.9%.
Is Lucid Diagnostics' PS Ratio too high?
Lucid Diagnostics' current PS Ratio of 24.77 is near median its 10-year median of 26.96. Over the past 10 years, this metric has ranged from a low of 8.68 to a high of 2,178.00. The Medical Devices & Instruments industry median PS Ratio is 2.86. Lucid Diagnostics' value of 24.77 is 766.1% above this industry median. Based on the distribution chart, Lucid Diagnostics ranks #739 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' PS Ratio compare to TLSI and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #739 out of 804 companies for PS Ratio. This places Lucid Diagnostics in the lower half of its industry. The industry median PS Ratio is 2.86. Lucid Diagnostics' value of 24.77 is 766.1% above this benchmark. Historically, Lucid Diagnostics' own PS Ratio has ranged from 8.68 to 2,178.00 over the past decade. While the company's 10-year median is 26.96 vs. the industry median of 2.86, Lucid Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current PS Ratio of 24.77 is 766.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current PS Ratio is 24.77, which is near median its own 10-year median of 26.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.07 — trading 31.5% above its estimated fair value. The current PS Ratio is 24.77, which is near median its 10-year median of 26.96 and 766.1% above the Medical Devices & Instruments industry median of 2.86. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current PS Ratio is 24.77 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81.
GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.
Key valuation signals for LUCD:
PS Ratio: 24.77 (near median its 10-year median of 26.96)
GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
Industry Position: 766.1% above the Medical Devices & Instruments median (#739 of 804)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score
Get the complete analysis for LUCD
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
